Werewolf Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Werewolf Therapeutics Inc. | HOWL - NASDAQ |
$15.00-$17.00 | $16.00 | $18.21 | 7.5 million | 4/30/2021 |
| Jefferies, SVB Leerink, Evercore ISI | ||||||
Co-Manager(s): H.C. Wainwright & Co. | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-04-08 Terms Added 2021-04-26 | ||||||
Werewolf Therapeutics Inc. Quote & Chart - Click for current quote - HOWL
IPO Boutique aggregates information on public companies and private companies, such as "HOWL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Werewolf Therapeutics Inc. (adapted from Werewolf Therapeutics Inc. prospectus):
They are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "HOWL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.